Targeted delivery of proteins to the intestines for treating inflammatory bowel diseases
Official title: Platform technology for targeted delivery of proteins to the intestines
Funded at Vitakey, INC. · NIH-10922023 · Data updated 2026-11-12
This study is working on a new way to deliver medicine directly to the intestines to help people with inflammatory bowel diseases like ulcerative colitis, making treatments more effective and easier on the body.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vitakey, INC. NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project start | September 20, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $349,037 |
| NIH project number | 1R43DK140050-01 |
| Project ID | NIH-10922023 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with inflammatory bowel diseases, particularly those experiencing ulcerative colitis.
✕Less likely to help
Patients with non-inflammatory bowel conditions or those who do not have access to biologic therapies may not benefit from this research.
What this research studies
This research focuses on developing a new technology for the targeted delivery of therapeutic proteins specifically to the intestines, which is crucial for treating inflammatory bowel diseases (IBD) like ulcerative colitis. By improving the local delivery of biologics, the research aims to enhance treatment efficacy while minimizing systemic side effects and reducing the overall cost of therapy. The approach addresses significant challenges such as the inactivation of biologics by digestive processes and aims to create a more effective treatment option for patients suffering from IBD.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for patients with inflammatory bowel diseases.
How similar studies have gone: Other research has shown promise in targeted delivery systems for biologics, indicating potential for success with this novel approach.
Where this research is happening
-
Vitakey, INC.
Washington, United States Active
Researchers
- Principal investigator: Anselmo, Aaron C — Vitakey, INC.
- Study coordinator: Anselmo, Aaron C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.